Shares of Biogen Inc. BIIB shed 2.06% to $160.85 Tuesday, on what proved to be an all-around mixed trading session for the ...

Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...

Palantir Technologies leads the list of a half dozen companies that could be added to the $26 trillion Nasdaq 100 index at ...

Box, Inc. (NYSE:BOX), the leading Intelligent Content Management (ICM) platform, today announced preliminary financial ...

We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where ...

On Monday, Biogen Inc (BIIB) stock saw a modest uptick, ending the day at $164.23 which represents a slight increase of $3.60 or 2.24% from the prior close of $160.63. The stock opened at $160.16 and ...

After about five years working behind the scenes, Arrakis Therapeutics is unveiling that its lead program will aim to treat ...

Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...

The Manufacturers Life Insurance Company lessened its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 1.8% ...

TOKYO: Japan’s Nikkei share average edged down on Wednesday, with investors booking profit after two straight days of gains ...

On Friday, Biogen Inc (BIIB) stock saw a modest uptick, ending the day at $160.51 which represents a slight increase of $0.68 or 0.43% from the prior close of $159.83. The stock opened at $160.72 and ...

The article summarizes current notable health news, including Biogen's Alzheimer's drug growth, mysterious disease in Congo, ...